Fundamental analysis · SEC EDGAR · TTM through 27/06/2026
MDLN · Nasdaq · Healthcare
Fundamental quality
65
out of 100
Medline Inc. is going through a tough financial stretch: it hasn't been profitable over the last twelve months. On fundamental quality it scores 65 out of 100, profiling it as a company of reasonable quality. Its weakest area is its profitability (net margin 3.2%). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Medline is America's largest medical-supplies maker and distributor: gloves, gowns, dressings and hundreds of thousands of products hospitals consume daily, with its own brand and integrated logistics. A discreet giant newly arrived on the stock market after decades as a family company.
EPS growth: 77% · Revenue growth: 10.7%
Net margin: 3.2% · ROE: 8.4% · ROIC: 6.8%
Net debt/EBITDA: 3.61x · FCF: 5.2%
Source: SEC EDGAR · TTM through 27/06/2026
The score combines growth, profitability and financial strength. Here its growth weighs in its favor, while its profitability drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2023 | 23,231 | 234 | 1,410 | -1,585 |
| 2024 | 25,507 | 1,163 | 1,415 | 16,293 |
| 2025 | 28,432 | 1,159 | 1,297 | 10,621 |
Between 2023 and 2025, revenue went from $23,231M to $28,432M (+22%) and net income went from $234M to $1,159M (+395%). Meanwhile, its margins have widened (from 1% to 4%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 27, 2026, versus the half-year ended June 28, 2025 (SEC filings):
Compared with the previous close (March 28, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
This company doesn't pay a dividend: it reinvests all its earnings back into the business.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Medline Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Medline Inc. a good company to invest in?
In terms of business quality, Medline Inc. scores 65 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Medline Inc. a profitable company?
Medline Inc. is profitable, with a net margin of 3.2%, though a thin one.
Does Medline Inc. have a lot of debt?
Yes, its leverage is high: net debt is 3.61 times its EBITDA, and it has been rising.
Is Medline Inc. growing?
Its revenue has grown 10.7% annualized in recent years and its earnings per share 77%.
Does Medline Inc. generate cash?
Yes. It converts about 5.2% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Insulet (PODD) · Edwards Lifesciences (EW) · Molina Healthcare (MOH) · Tenet Healthcare (THC) · Universal Health Services (UHS) · Teva Pharmaceutical Industries (TEVA) · see more →
Who's behind the methodology and model · how the score is computed
Data: see Medline Inc.'s filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.